Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 7
2005 6
2006 12
2007 6
2008 11
2009 24
2010 28
2011 28
2012 26
2013 35
2014 42
2015 37
2016 48
2017 65
2018 57
2019 50
2020 80
2021 101
2022 87
2023 98
2024 104
2025 133
2026 55

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,031 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jianjun wu (533 results)?
Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer.
Li W, Zhou C, Yu L, Hou Z, Liu H, Kong L, Xu Y, He J, Lan J, Ou Q, Fang Y, Lu Z, Wu X, Pan Z, Peng J, Lin J. Li W, et al. Among authors: wu x. Autophagy. 2024 Jan;20(1):114-130. doi: 10.1080/15548627.2023.2249762. Epub 2023 Aug 29. Autophagy. 2024. PMID: 37615625 Free PMC article.
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial.
Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, Lu ZH, Wang QX, Sun R, Cai PQ, Zhu CM, Liu M, Li JB, Wang YR, Jin Y, Wang F, Luo HT, Li CL, Pan ZZ, Xu RH. Xiao WW, et al. Cancer Cell. 2024 Sep 9;42(9):1570-1581.e4. doi: 10.1016/j.ccell.2024.07.004. Epub 2024 Aug 1. Cancer Cell. 2024. PMID: 39094560 Free article. Clinical Trial.
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Initial Results of a Phase III Trial.
Mei WJ, Wang XZ, Li YF, Sun YM, Yang CK, Lin JZ, Wu ZG, Zhang R, Wang W, Li Y, Zhuang YZ, Lei J, Wan XB, Ren YK, Cheng Y, Li WL, Wang ZQ, Xu DB, Mo XW, Ju HX, Ye SW, Zhao JL, Zhang H, Gao YH, Zeng ZF, Xiao WW, Zhang XP, Zhang X, Xie E, Feng YF, Tang JH, Wu XJ, Chen G, Li LR, Lu ZH, Wan DS, Bei JX, Pan ZZ, Ding PR. Mei WJ, et al. Ann Surg. 2023 Apr 1;277(4):557-564. doi: 10.1097/SLA.0000000000005780. Epub 2022 Dec 20. Ann Surg. 2023. PMID: 36538627 Free PMC article. Clinical Trial.
Cancer associated fibroblasts-derived lactate induces oxaliplatin treatment resistance by promoting cancer stemness via ANTXR1 lactylation in colorectal cancer.
He J, Li W, Wang S, Lan J, Hong X, Liao L, Kang D, Wang W, Wang R, Zhang W, Yu L, Ou Q, Fang Y, Wu X, Lin J, Ding P, Zhou C, Pan Z, Peng J. He J, et al. Among authors: wu x. Cancer Lett. 2025 Oct 28;631:217917. doi: 10.1016/j.canlet.2025.217917. Epub 2025 Jul 17. Cancer Lett. 2025. PMID: 40683418 Free article.
Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH. Wang DS, et al. PLoS Med. 2024 May 10;21(5):e1004389. doi: 10.1371/journal.pmed.1004389. eCollection 2024 May. PLoS Med. 2024. PMID: 38728364 Free PMC article. Clinical Trial.
Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH, Xiao BY, Li DD, Jiang W, Ding Y, Wu XJ, Zhang RX, Lin JZ, Wang W, Han K, Kong LH, Zhang XK, Chen BY, Mei WJ, Pan ZZ, Tang JH, Zhang XS, Ding PR. Yu JH, et al. Lancet Oncol. 2024 Jul;25(7):843-852. doi: 10.1016/S1470-2045(24)00203-1. Epub 2024 Jun 6. Lancet Oncol. 2024. PMID: 38852601 Clinical Trial.
Deriving consensus sepsis clusters via goal-directed subgroup identification in multi-omics study.
Zhang Z, Chen L, Shen H, Wang J, Yang J, Yang S, Zhang W, Jiang X, Wu X, Meng X, Zhao F, Gu W, Yin H, Wang L, Yu Y, Cheng L, Xu P, Fei D, Yu H, Shen X, Jin Y, Liu B, Sun J, Ni H, Atreya MR, Elbers PWG, Ho KM, Celi LA; Chinese Multi-omics Advances In Sepsis (CMAISE) Consortium. Zhang Z, et al. Among authors: wu x. Nat Commun. 2025 Nov 24;16(1):10328. doi: 10.1038/s41467-025-65271-4. Nat Commun. 2025. PMID: 41285725 Free PMC article.
Targeting farnesoid X receptor as aging intervention therapy.
Zhang L, Yu J, Gao X, Yan Y, Wang X, Shi H, Fang M, Liu Y, Kim YB, Zhu H, Wu X, Huang C, Fan S. Zhang L, et al. Among authors: wu x. Acta Pharm Sin B. 2025 Mar;15(3):1359-1382. doi: 10.1016/j.apsb.2025.01.006. Epub 2025 Jan 19. Acta Pharm Sin B. 2025. PMID: 40370561 Free PMC article.
1,031 results